Page 96 - Read Online

domains. Nat Rev Mol Cell Biol 2008;9:99-111. endothelial compartment. Cancer Res 2003;63:3585-92.
11. Hatanpaa KJ, Burma S, Zhao D, Habib AA. Epidermal growth factor 29. Garlich JR, De P, Dey N, Su JD, Peng X, Miller A, Murali R, Lu Y,
receptor in glioma: signal transduction, neuropathology, imaging, Mills GB, Kundra V, Shu HK, Peng Q, Durden DL. A vascular targeted
and radioresistance. Neoplasia 2010;12:675-84. pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with
12. Quayle SN, Lee JY, Cheung LW, Ding L, Wiedemeyer R, Dewan antitumor and antiangiogenic activity. Cancer Res 2008;68:206-15.
RW, Huang-Hobbs E, Zhuang L, Wilson RK, Ligon KL, Mills 30. Koul D, Shen R, Kim YW, Kondo Y, Lu Y, Bankson J, Ronen SM,
GB, Cantley LC, Chin L. Somatic mutations of PIK3R1 promote Kirkpatrick DL, Powis G, Yung WK. Cellular and in vivo activity of
gliomagenesis. PloS one 2012;7:e49466. a novel PI3K inhibitor, PX-866, against human glioblastoma. Neuro
13. Castellino RC, Barwick BG, Schniederjan M, Buss MC, Becher Oncol 2010;12:559-69.
O, Hambardzumyan D, Macdonald TJ, Brat DJ, Durden DL. 31. Pitz MW, Eisenhauer EA, MacNeil MV, Thiessen B, Easaw JC,
Heterozygosity for Pten promotes tumorigenesis in a mouse model Macdonald DR, Eisenstat DD, Kakumanu AS, Salim M, Chalchal
of medulloblastoma. PloS one 2010;5:e10849. H, Squire J, Tsao MS, Kamel-Reid S, Banerji S, Tu D, Powers J,
14. Zhao D, Besser AH, Wander SA, Sun J, Zhou W, Wang B, Ince Hausman DF, Mason WP. Phase II study of PX-866 in recurrent
T, Durante MA, Guo W, Mills G, Theodorescu D, Slingerland glioblastoma. Neuro Oncol 2015;17:1270-4.
J. Cytoplasmic p27 promotes epithelial-mesenchymal transition 32. Sharma PS, Sharma R, Tyagi T. VEGF/VEGFR pathway inhibitors
and tumor metastasis via STAT3-mediated Twist1 upregulation. as anti-angiogenic agents: present and future. Curr Cancer Drug
Oncogene 2015;34:5447-59. Targets 2011;11:624-53.
15. Yoshioka K, Yoshida K, Cui H, Wakayama T, Takuwa N, Okamoto Y, 33. Reardon DA, Turner S, Peters KB, Desjardins A, Gururangan
Du W, Qi X, Asanuma K, Sugihara K, Aki S, Miyazawa H, Biswas S, Sampson JH, McLendon RE, Herndon JE 2nd, Jones LW,
K, Nagakura C, Ueno M, Iseki S, Schwartz RJ, Okamoto H, Sasaki T, Kirkpatrick JP, Friedman AH, Vredenburgh JJ, Bigner DD, Friedman
Matsui O, Asano M, Adams RH, Takakura N, Takuwa Y. Endothelial HS. A review of VEGF/VEGFR-targeted therapeutics for recurrent
PI3K-C2alpha, a class II PI3K, has an essential role in angiogenesis glioblastoma. J Natl Compr Canc Netw 2011;9:414-27.
and vascular barrier function. Nat Med 2012;18:1560-9. 34. Kuczynski EA, Patten SG, Coomber BL. VEGFR2 expression and
16. Holand K, Boller D, Hagel C, Dolski S, Treszl A, Pardo OE, TGF-beta signaling in initial and recurrent high-grade human glioma.
Cwiek P, Salm F, Leni Z, Shepherd PR, Styp-Rekowska B, Djonov Oncology 2011;81:126-34.
V, von Bueren AO, Frei K, Arcaro A. Targeting class IA PI3K 35. Chinot OL, de La Motte Rouge T, Moore N, Zeaiter A, Das A,
isoforms selectively impairs cell growth, survival, and migration in Phillips H, Modrusan Z, Cloughesy T. AVAglio: Phase 3 trial
glioblastoma. PloS one 2014;9:e94132. of bevacizumab plus temozolomide and radiotherapy in newly
17. Huse JT, Holland EC. Targeting brain cancer: advances in the diagnosed glioblastoma multiforme. Adv Ther 2011;28:334-40.
molecular pathology of malignant glioma and medulloblastoma. Nat 36. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY,
Rev Cancer 2010;10:319-31. Olson JJ. Exciting new advances in neuro-oncology: the avenue to a
18. Dimitrova V, Arcaro A. Targeting the PI3K/AKT/mTOR signaling cure for malignant glioma. CA Cancer J Clin 2010;60:166-93.
pathway in medulloblastoma. Curr Mol Med 2015;15:82-93. 37. Hardee ME, Zagzag D. Mechanisms of glioma-associated
19. Nagy JA, Dvorak HF. Heterogeneity of the tumor vasculature: the neovascularization. Am J Pathol 2012;181:1126-41.
need for new tumor blood vessel type-specific targets. Clin Exp 38. Takano S, Yamashita T, Ohneda O. Molecular therapeutic targets for
Metastasis 2012;29:657-62. glioma angiogenesis. J Oncol 2010;2010:351908.
20. Schmid MC, Varner JA. Myeloid cell trafficking and tumor 39. di Tomaso E, Snuderl M, Kamoun WS, Duda DG, Auluck PK,
angiogenesis. Cancer Lett 2007;250:1-8. Fazlollahi L, Andronesi OC, Frosch MP, Wen PY, Plotkin SR, Hedley-
21. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Whyte ET, Sorensen AG, Batchelor TT, Jain RK. Glioblastoma
Georgescu MM, Simons JW, Semenza GL. Modulation of hypoxia- recurrence after cediranib therapy in patients: lack of “rebound”
inducible factor 1alpha expression by the epidermal growth factor/ revascularization as mode of escape. Cancer Res 2011;71:19-28.
phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human 40. Gerstner ER, Chen PJ, Wen PY, Jain RK, Batchelor TT, Sorensen
prostate cancer cells: implications for tumor angiogenesis and G. Infiltrative patterns of glioblastoma spread detected via diffusion
therapeutics. Cancer Res 2000;60:1541-5. MRI after treatment with cediranib. Neuro Oncol 2010;12:466-72.
22. Xia C, Meng Q, Cao Z, Shi X, Jiang BH. Regulation of angiogenesis 41. Navis AC, Bourgonje A, Wesseling P, Wright A, Hendriks W, Verrijp
and tumor growth by p110 alpha and AKT1 via VEGF expression. J K, van der Laak JA, Heerschap A, Leenders WP. Effects of dual
Cell Physiol 2006;209:56-66. targeting of tumor cells and stroma in human glioblastoma xenografts
23. Brazil DP, Park J, Hemmings BA. PKB binding proteins. Getting in with a tyrosine kinase inhibitor against c-MET and VEGFR2. PloS
on the Akt. Cell 2002;111:293-303. one 2013;8:e58262.
24. Galetic I, Andjelkovic M, Meier R, Brodbeck D, Park J, Hemmings 42. Bridges E, Harris AL. Vascular-promoting therapy reduced tumor
BA. Mechanism of protein kinase B activation by insulin/insulin-like growth and progression by improving chemotherapy efficacy. Cancer
growth factor-1 revealed by specific inhibitors of phosphoinositide cell 2015;27:7-9.
3-kinase-significance for diabetes and cancer. Pharmacol Ther 43. Donnem T, Hu J, Ferguson M, Adighibe O, Snell C, Harris AL,
1999;82:409-25. Gatter KC, Pezzella F. Vessel co-option in primary human tumors
25. Hu L, Hofmann J, Jaffe RB. Phosphatidylinositol 3-kinase mediates and metastases: an obstacle to effective anti-angiogenic treatment?
angiogenesis and vascular permeability associated with ovarian Cancer Med 2013;2:427-36.
carcinoma. Clin Cancer Res 2005;11:8208-12. 44. Qian CN. Hijacking the vasculature in ccRCC-co-option, remodelling
26. Schmid MC, Avraamides CJ, Dippold HC, Franco I, Foubert P, and angiogenesis. Nat Rev Urol 2013;10:300-4.
Ellies LG, Acevedo LM, Manglicmot JR, Song X, Wrasidlo W, 45. Nguyen TM, Subramanian IV, Kelekar A, Ramakrishnan S. Kringle
Blair SL, Ginsberg MH, Cheresh DA, Hirsch E, Field SJ, Varner 5 of human plasminogen, an angiogenesis inhibitor, induces
JA. Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate both autophagy and apoptotic death in endothelial cells. Blood
myeloid cell PI3kgamma, a single convergent point promoting tumor 2007;109:4793-802.
inflammation and progression. Cancer cell 2011;19:715-27. 46. Ramakrishnan S, Nguyen TM, Subramanian IV, Kelekar A.
27. Semenza GL. HIF-1 and tumor progression: pathophysiology and Autophagy and angiogenesis inhibition. Autophagy 2007;3:512-5.
therapeutics. Trends Mol Med 2002;8:S62-7. 47. Du J, Teng RJ, Guan T, Eis A, Kaul S, Konduri GG, Shi Y. Role of
28. Su JD, Mayo LD, Donner DB, Durden DL. PTEN and autophagy in angiogenesis in aortic endothelial cells. Am J Physiol
phosphatidylinositol 3’-kinase inhibitors up-regulate p53 and block Cell Physiol 2012;302:C383-91.
tumor-induced angiogenesis: evidence for an effect on the tumor and 48. Shen W, Tian C, Chen H, Yang Y, Zhu D, Gao P, Liu J. Oxidative

86
Journal of Cancer Metastasis and Treatment ¦ Volume 2 ¦ March 11, 2016 ¦